What changed for Bladder Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Bladder Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 1,554 to 1,560 (+6)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Bladder Cancer in July 2026. Voxsanity tracks 7 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 73 trials tracked for Bladder Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03924895 · results posted 30 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03924895) enrolled a total of 595 people with muscle-invasive bladder cancer across three groups: 166 people received pembrolizumab (an immunotherapy medicine) followed by surgery (Arm A); 259 people had surgery alone (Arm B); and 170 people received a combination of two medicines — enfortumab vedotin and pembrolizumab — followed by surgery (Arm C). The trial was primarily measuring "event-free survival," which refers to how long participants went without their disease getting worse, without being unable to have surgery, o...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04822350 · results posted 2 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 596 participants, all of whom were included in the overall study count with no participants recorded as having left the study early. A slightly smaller group of 589 people were included in the main analysis set. The trial was measuring how long participants lived after starting treatment with a medicine called avelumab — a type of immunotherapy — which was given as a maintenance (ongoing) treatment after chemotherapy for bladder and urinary tract cancer. The study also looked at how long it took before the cancer show...
-
NCT04055311 · results posted 19 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04055311) involved people who had undergone surgery to remove the bladder due to cancer, along with their caregivers. In total, 174 people started the trial — 47 bladder cancer survivors and 31 caregivers in the intervention group, and 62 survivors and 34 caregivers in a comparison group called "usual care enhanced." The trial tracked participants over 12 months (at 1, 3, 6, and 12 months), and by the end, 28 intervention survivors, 16 intervention caregivers, 38 usual care enhanced survivors, and 26 usual care enhanced ca...
-
NCT04165317 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04165317) enrolled 1,068 participants across five groups. Three of those groups made up the main comparison (Cohort A), each with around 350 people, and two smaller groups (Cohort B1 and B2) had 5 and 8 participants respectively. The trial was looking at a drug called PF-06801591 (sasanlimab) given alone or alongside BCG — a long-established bladder treatment — in people with a type of bladder cancer that had not yet grown into the muscle wall. The main thing being measured was "event-free survival," meaning how long peopl...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03747419 · results posted 31 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 participants, and all 14 completed the study. The trial was looking at a combination of a drug called avelumab (a type of immunotherapy) and radiation therapy directed at the bladder. The main thing researchers were measuring was whether participants showed a "complete clinical response" — meaning no sign of disease on a camera inspection of the bladder (cystoscopy), a urine test, and a body scan — at three months after finishing radiation, with further checks continuing for up to three years. The reported data sh...
-
NCT01382706 · results posted 9 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01382706) enrolled 15 participants, all of whom were in a single treatment group. Of those, 13 completed the study and 2 did not. The trial was looking at two things: how long participants went without their condition getting worse (called "progression-free survival"), and how often serious unwanted medical events of a certain severity occurred. The reported data shows that the median progression-free survival — that is, the midpoint estimate for how long participants went before their condition progressed or they passed...
-
NCT04149574 · results posted 16 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04149574) enrolled 12 participants in total — 8 in Arm A and 4 in Arm B. All 12 participants completed the study, with none recorded as dropping out. The trial was designed to investigate treatments for a form of bladder cancer, and it was structured in two parts. The main things it set out to measure in Part 2 included how long participants went without their disease coming back or worsening (called "event-free survival"), how long they lived overall, and whether the disease had cleared up at a 13-week check. The reporte...
-
NCT04172675 · results posted 1 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04172675) enrolled 107 participants across four groups studying a drug called erdafitinib in people with bladder cancer. The largest group — 49 people — received erdafitinib and was compared against a group of 24 people who received a treatment of their doctor's choice (Cohort 1). A further 16 people received erdafitinib in a second group (Cohort 2), and 18 people received it in a third group (Cohort 3). Nine participants from the doctor's-choice group later crossed over to receive erdafitinib. The trial was primarily meas...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03732677 · results posted 3 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03732677) enrolled 1,063 people with bladder cancer — 533 in the group receiving durvalumab combined with gemcitabine and cisplatin (chemotherapy), and 530 in the group receiving gemcitabine and cisplatin alone. The trial was primarily measuring two things: how many participants showed no detectable cancer in the bladder when it was surgically removed (called a "pathologic complete response"), and how long participants went without their disease coming back or worsening after they joined the trial (called "event-free survi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02122172 · results posted 25 April 2025
According to the results reported on ClinicalTrials.gov, 32 people took part in this trial of a drug called afatinib. All 32 participants were recorded as having completed the study. The group was split into two sub-groups: 23 people in a main Phase II study and 9 people in a separate "molecularly selected" cohort (meaning they were chosen based on specific features of their cancer cells). The trial was primarily measuring how many participants went for at least 3 months without their cancer growing or spreading — a period known as "progression-free survival." The reported data shows that, of...
-
NCT04586244 · results posted 10 March 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 people across five treatment groups, all receiving different combinations of investigational medicines before surgery for bladder cancer. The five groups were: epacadostat plus retifanlimab (3 people); retifanlimab alone (20 people); epacadostat alone (2 people); retifanlimab plus a medicine called INCAGN02385 (4 people); and a three-medicine combination adding INCAGN02390 to that last group (1 person). The trial was primarily measuring changes in a type of immune cell — called CD8+ lymphocytes — inside the tumour...
-
NCT02662062 · results posted 27 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 28 participants, all of whom received a treatment called pembrolizumab (an immunotherapy drug) alongside chemotherapy and radiation. The trial was investigating a combination treatment for bladder cancer. Of the 28 people who started, 27 completed the study. The trial was primarily looking at how many participants experienced what the researchers defined as an "unacceptable" level of serious side effects or treatment disruptions — for example, severe reactions, having to miss doses of chemotherapy, or radiation taking...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04314778 · results posted 24 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04314778) involved 61 people in total — 30 in the intervention group and 31 in a control group (who did not receive the intervention). Of those, 25 and 28 people respectively completed the study. The trial was measuring physical activity levels after surgery, specifically tracking daily step counts using a step-counting device. The main question was whether the intervention changed how much participants walked — first while still in hospital after surgery, and then again at three months after being discharged home. The re...
-
NCT03702179 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 32 people, all of whom received a combination of two immunotherapy medicines called durvalumab and tremelimumab, alongside radiotherapy, for muscle-invasive bladder cancer. All 32 participants completed the study. The trial was primarily looking at how many people showed a "pathological response" — meaning that after treatment, a biopsy (tissue sample) of the bladder showed no remaining muscle-invasive cancer. The reported data shows that, for the primary measure, 26 out of 32 participants showed this pathological re...
-
NCT01224665 · results posted 29 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 592 people with muscle-invasive bladder cancer who were having surgery to remove the bladder (called a radical cystectomy). Participants were randomly split into two groups: 300 received a standard lymph node removal (where nearby lymph nodes are taken out to check for cancer spread), and 292 received an extended lymph node removal (where a larger area of lymph nodes was removed). The trial was measuring whether removing more lymph nodes made a difference to how long people lived without their cancer coming back, and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02619253 · results posted 18 November 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 52 people across five groups. There were two smaller "dose-finding" groups (4 people each) used to work out a safe dosing level for the combination of two drugs — vorinostat and pembrolizumab. The remaining 44 people were split across three "expansion" groups (roughly 14–15 people each), made up of different cancer types. The trial was primarily measuring how many participants' tumours shrank or disappeared, and how long participants went without their disease getting worse. The reported data shows that, looking at t...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05012397 · results posted 17 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 40 people who all had advanced or metastatic solid tumours (cancers that had spread) carrying a specific genetic change called MDM2 gene amplification. All 40 participants received the study drug, milademetan (also called RAIN-32). By the time the trial ended, 14 participants had completed the study and 26 had not completed it. The trial was primarily measuring how often the drug caused tumours to shrink or disappear — known as the "overall response rate" — and also tracked several secondary measures related to how lo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04548193 · results posted 28 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04548193) enrolled 49 people in total — 25 in the experimental group (Arm A) and 24 in the control group (Arm B). The trial was measuring whether people in the experimental group changed how much cruciferous vegetables (such as broccoli, cabbage, and cauliflower) they ate, and whether that change showed up in their urine levels of a natural compound called isothiocyanates (a substance found in these vegetables that can be detected as a marker of intake). The study also looked at changes in gene activity as a secondary meas...
-
NCT02554812 · results posted 30 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02554812) enrolled a total of 457 participants across 27 different treatment groups. It tested several different combinations of investigational medicines — including avelumab, utomilumab, PF-04518600, PD-0360324, and CMP-001 — in people with various types of cancer, including non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, triple-negative breast cancer, and small cell lung cancer. The trial had two main stages: an early "Phase 1b" stage focused on finding out whether the drug combinations caused certai...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT01489813 · results posted 25 July 2024
According to the results reported on ClinicalTrials.gov, this trial involved 36 men in total — 16 in a sugar pill (placebo) group and 20 in a genistein supplement group. Genistein is a naturally occurring compound found in soy. The trial was measuring changes in urinary symptoms over 6 weeks, using a standard questionnaire called the International Prostate Symptom Score (IPSS). This questionnaire gives a score between 0 and 35, where a lower score means fewer or less bothersome urinary symptoms. The trial also looked at whether cancer was detected at a biopsy done around 10 weeks into the stud...
-
NCT04209114 · results posted 27 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04209114) involved 114 people with bladder cancer who were split into three groups: one group received a combination of two medicines called nivolumab and bempegaldesleukin (37 people), one group received nivolumab alone (37 people), and one group received standard of care treatment (40 people). The trial was measuring two main things: whether any cancer remained in tissue removed during surgery (called a "pathologic complete response"), and how long people went without their disease getting worse or dying (called "event-f...
-
NCT04525131 · results posted 18 June 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 12 participants, all of whom completed the study. The trial was testing a treatment called CPX-POM and was primarily focused on tracking unwanted health events (called adverse events) that participants experienced, including how serious those events were and whether any participant had to miss too many doses because of them. The reported data shows that out of the 12 participants, 9 experienced at least one adverse event (an unwanted health occurrence during the trial). One participant experienced a serious adverse e...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03621982 · results posted 13 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03621982) enrolled 83 people in total across 14 different dose groups. Participants received either ADCT-301 (also called camidanlumab tesirine) on its own at one of eight different dose levels, or ADCT-301 combined with another drug called pembrolizumab at one of six different dose levels. The trial was primarily measuring what happened to participants in terms of medical events, serious medical events, and any changes to their dosing during the study period — in other words, it was tracking what occurred while people wer...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02451423 · results posted 31 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02451423) enrolled 23 people with bladder cancer across three groups: 6 received a single dose of atezolizumab (also known as MPDL3280A) before surgery, 6 received two doses, and 11 received three doses. All 23 participants completed the study. The trial was primarily measuring how certain immune cells — different types of T cells, which are part of the body's immune system — changed in bladder tumour tissue between a biopsy taken before treatment and tissue removed during surgery. It also tracked whether treatment caused...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04046094 · results posted 4 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04046094) enrolled 12 participants, all of whom received intravenous (IV) ascorbic acid (a form of vitamin C given directly into the bloodstream). All 12 participants completed the trial with none dropping out. The trial was looking at people with bladder cancer, and the main thing it set out to measure was the stage of the cancer — essentially how far it had spread — after treatment, based on tissue examined following surgery. Two further outcomes were also planned: participants' quality of life (using a bladder-cancer-sp...
-
NCT04806334 · results posted 26 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 participants, all of whom were in a single group that underwent a combination of a specialised MRI scan of the pelvis and bladder (called 4D MRI) along with genetic analysis of their bladder tumour. The trial was exploring what is known as "radiogenomics" — linking information from medical imaging with information from the genetic makeup of a tumour. Ten of the 11 participants completed the study, and one did not complete it (the reason was not reported in the data). The reported data shows that the trial had one...
-
NCT02807636 · results posted 13 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,213 people across three groups: 400 received a placebo combined with chemotherapy drugs (gemcitabine and carboplatin or cisplatin), 451 received the immunotherapy drug atezolizumab combined with the same chemotherapy, and 362 received atezolizumab on its own. The trial was measuring two main things: how long participants lived without their disease getting worse (called progression-free survival), and how long participants lived overall (called overall survival). The reported data shows that none of the participants...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04045613 · results posted 13 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04045613) enrolled a total of 95 participants across seven different treatment groups, organised into five "substudies." Each substudy tested different doses and combinations of two medicines — derazantinib and atezolizumab — in people with certain types of cancer. The trial was measuring things like how many participants' tumours shrank or disappeared, how long any such response lasted, and — for one substudy — what dose of the combination was considered suitable to take forward into further research. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03519256 · results posted 1 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03519256) enrolled 69 people across four treatment groups: 16 received nivolumab alone (Arm A), 26 received nivolumab plus a bladder treatment called BCG (Arm B), 17 received nivolumab plus an experimental drug called BMS-986205 (Arm C), and 10 received all three treatments combined (Arm D). The trial was primarily measuring the number of participants who experienced medical events — called adverse events — during the course of the study, including serious events, events that led to stopping treatment, immune-related react...
-
NCT03785925 · results posted 28 March 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 188 people, all of whom received a combination of two drugs — bempegaldesleukin (also called NKTR-214) and nivolumab. Of those, 172 completed the study and 16 did not. The trial was primarily looking at what is called the "objective response rate" (ORR) — that is, the proportion of participants whose tumours showed a meaningful reduction in size, either disappearing completely or shrinking by at least 30% — specifically in people whose tumours had low levels of a protein called PD-L1 (a marker sometimes used to guide...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
See all 73 reported results for Bladder Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research money has been directed toward bladder cancer, which suggests the condition has attracted meaningful scientific attention. However, the direction of that funding has been falling year on year, meaning the field may be receiving less financial support over time than it once did. For patients, this pattern is worth watching, as s...
See the full Bladder Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.